Significance of Perioperative Variations in Circulating Tumor Cells in Resectable Colorectal Cancer
-
By
-
Qiang Feng
-
Chen Ni
-
Fangmin Zhou
-
Junjia Zhu
-
Xia Sun
-
Ya Qin
-
Nan Xiang
-
Dan Wu
-
November 3, 2025
-
Clinical Scorecard: Significance of Perioperative Variations in Circulating Tumor Cells in Resectable Colorectal Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Resectable colorectal cancer |
| Key Mechanisms | Circulating tumor cells (CTCs) enter peripheral blood from primary tumor or metastases, contributing to metastasis and recurrence |
| Target Population | Patients with newly diagnosed colorectal cancer undergoing radical resection |
| Care Setting | Surgical oncology and perioperative clinical monitoring |
Key Highlights
- CTCs are viable tumor cells in blood that reflect tumor stage, diagnosis, and prognosis in colorectal cancer.
- Perioperative changes in CTC counts can indicate tumor dissemination during surgery and potential for recurrence.
- Microfluidic chip technology enables high-purity isolation and quantification of CTCs for dynamic monitoring.
Guideline-Based Recommendations
Diagnosis
- Use pathological biopsy for initial colorectal cancer diagnosis.
- Employ CTC detection pre- and post-surgery for real-time monitoring of tumor cell dissemination.
Management
- Consider CTC counts for stratifying patients to guide intensity of postoperative treatments.
- Use CTC dynamics to inform prognosis and tailor individualized therapeutic plans.
Monitoring & Follow-up
- Collect peripheral blood samples before and after surgery to detect CTC variations.
- Repeat CTC testing to dynamically assess treatment efficacy and early signs of metastasis.
Risks
- Surgical manipulation may dislodge tumor cells into circulation, increasing metastasis risk.
- Low CTC counts require sensitive isolation techniques to avoid false negatives.
Patient & Prescribing Data
81 colorectal cancer patients undergoing radical resection with paired pre- and postoperative blood samples
CTC quantification can identify patients at higher risk of lymph node metastasis and recurrence, supporting personalized treatment decisions.
Clinical Best Practices
- Exclude patients with confounding conditions such as autoimmune diseases or infections to ensure accurate CTC assessment.
- Use microfluidic chip technology for sensitive and specific CTC isolation from peripheral blood.
- Integrate CTC monitoring with conventional imaging and tumor markers for comprehensive perioperative evaluation.
References
